Abstracts tagged "Biologic agents"

Abstract Number: 921 • 2014 ACR/ARHP Annual Meeting
Comparison of Infection Rates in Patients Receiving Denosumab, Denosumab and Biologics and Biologics Alone in a Suburban Rheumatology Clinic
Sajina Prabhakaran¹ and Charles Pritchard², ¹Drexel Rheumatology, Drexel University College of Medicine, Philadelphia, PA, ²Drexel University College of Medicine, Willow Grove, PA
Background/Purpose: Biologics including rituximab, abatacept and belimumab increase the risk of infection in patients. Denosumab, a RANK-ligand inhibitor used in the treatment of osteoporosis may…
Abstract Number: 2833 • 2014 ACR/ARHP Annual Meeting
SM101, a Novel Recombinant, Soluble, Human FcγIIB Receptor, in the Treatment of Systemic Lupus Erythematosus: Results of a Double-Blind, Placebo-Controlled Multicenter Study
Sascha Tillmanns¹, Claudia Kolligs¹, David P. D'Cruz², Andrea Doria³, Eric Hachulla⁴, Reinhard E. Voll⁵, Michael Tansey¹ and Klaus Schollmeier⁶, ¹Medical/Clinical, SuppreMol GmbH, Martinsried, Germany, ²Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom, ³Department of Medicine - DIMED, University of Padova, Padova, Italy, ⁴Medicine Interne et Oncologie Medicale Centre Pole, Lille University, Lille, France, ⁵Rheumatology and Clinical Immunology & Centre of Chronic Immunodeficiency, University Hospital Freiburg, Freiburg, Germany, ⁶SuppreMol GmbH, Martinsried, Germany
Background/Purpose : SM101, which represents the human soluble non-glycosylated version of the Fcγ receptor IIB, binds to the Fc part of autoimmune complexes and inhibits…
Abstract Number: 2122 • 2014 ACR/ARHP Annual Meeting
Variation in the Prescribing Practices of Biologic Dmards
Heather O. Tory¹, Josephine A. Awosogba², Amish J. Dave², Jonathan S. Coblyn², Daniel H. Solomon² and Sonali P. Desai², ¹Rheumatology Program, Division of Immunology, Boston Children's Hospital, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Biologic DMARDs (bDMARDs) are effective yet expensive treatments for RA. Variability in the prescribing practices of rheumatologists using these agents may be attributable to…
Abstract Number: 932 • 2014 ACR/ARHP Annual Meeting
MRP8/14 Serum Level As Predictor of Response to Starting and Stopping Anti-TNF Treatment in Non-Systemic Juvenile Idiopathic Arthritis
Janneke Anink¹, Marieke H. Otten¹, Lisette W.A. van Suijlekom-Smit¹, Marion A.J. Van Rossum², Koert M. Dolman³, Esther P.A. Hoppenreijs⁴, Rebecca ten Cate⁵, Simona Ursu⁶, Lucy R Wedderburn⁷, Gerd Horneff⁸, Thomas Vogl^9,10, Dirk Föll^10,11, Johannes Roth^9,12 and Dirk Holzinger^10,13, ¹Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, ²Pediatric Rheumatology, Emma Kinderziekenhuis Academic Medical Center, Amsterdam, Netherlands, ³Pediatric Rheumatology, St. Lucas Andreas Hospital and Reade Institute, Amsterdam, Netherlands, ⁴Pediatric Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ⁵Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Rheumatology Unit, Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, ⁷Rheumatology Unit, Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁸Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁹Immunology, Institute of Immunology University of Muenster, Muenster, Germany, ¹⁰Interdisciplinary Centre for Clinical Research IZKF, University Hospital Muenster, Muenster, Germany, ¹¹Pediatric Rheumatology and Immunology, University Children's Hospital Muenster, Muenster, Germany, ¹²University Hospital Muenster, Muenster, Germany, ¹³Pediatric Rheumatology and Immunology, University Children’s Hospital Muenster, Muenster, Germany
Background/Purpose: Biological therapy has dramatically improved the treatment of patients with JIA. However, there is still a group of patients that shows a lack of…
Abstract Number: 2611 • 2014 ACR/ARHP Annual Meeting
Short Term Efficacy of Tumor Necrosis Factor Inhibitors in Patients with non–radiographic Axial Spondylarthritis and ankylosing Spondylitis; Results from Turkbio Registry
Pinar Cetin¹, Umut Kalyoncu², Bunyamin Kisacik³, Ismail Sari¹, Dilek Solmaz⁴, Omer Karadag², Ahmet Mesut Onat³, Gezmis Kimyon⁵, Levent Kilic⁶, Fatos Onen¹, Sedat Kiraz², Merih Birlik¹, Ihsan Ertenli², Omer Nuri Pamuk⁷ and Nurullah Akkoc¹, ¹Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, ²Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey, ³Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ⁴Department of Internal Medicine, Division of Rheumatology, Namik Kemal University School of Medicine, Tekirdag, Turkey, ⁵Department of Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ⁶Rheumatology, HacettepeUniversity School of Medicine, Ankara, Turkey, ⁷Department of Rheumatology, Trakya University School of Medicine, Edirne, Turkey
Background/Purpose Axial spondylarthritis (AxSpA) has been proposed as an umbrella term for ankylosing spondylitis (AS) and non-radiographic (nr) AxSpA). This new concept makes diagnosis of…
Abstract Number: 1945 • 2014 ACR/ARHP Annual Meeting
Pharmacodynamic Effects of the CD22-Targeted Monoclonal Antibody Epratuzumab on B Cells in Patients with Systemic Lupus Erythematosus
Anthony Shock¹, Brian Kilgallen², Willem Koetse², Christian Stach³, Sabine Bongardt³ and Catrinel Galateanu⁴, ¹UCB Pharma, Slough, United Kingdom, ²UCB Pharma, Raleigh, NC, ³UCB Pharma, Monheim, Germany, ⁴UCB Pharma, Brussels, Belgium
Background/Purpose Epratuzumab is a humanized monoclonal antibody (mAb) that targets the B cell-specific protein CD22 and is currently in Phase 3 clinical trials in patients…
Abstract Number: 837 • 2014 ACR/ARHP Annual Meeting
Progressive Multifocal Leukoencephalopathy Associated with Biologic Therapy in Rheumatic Diseases: Strengthening Association with Rituximab
Eamonn Molloy¹ and Leonard H. Calabrese², ¹St Vincent University Hospital, Dublin, Ireland, ²Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose Progressive Multifocal Leukoencephalopathy (PML) is a rare and often fatal opportunistic infection recently associated with several biologic therapies. However, ascribing risk to individual therapies…
Abstract Number: 2576 • 2014 ACR/ARHP Annual Meeting
Diffusing Weight Magnetic Resonance Imaging May Suggest the Treatment Strategy in Ankylosing Spondylitis
Sang-Yeob Lee, Division of Rheumatology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, South Korea
Background/Purpose: With the advanced MRI techniques, pathologic features can be detected at an early stage and quantitatively evaluated, resulting in the advantages of early diagnosis…
Abstract Number: 1944 • 2014 ACR/ARHP Annual Meeting
Targeting CD22 with Epratuzumab Impacts Cytokine Production By B Cells
Vanessa Fleischer^1,2, Julia Sieber^1,2, Sarah J. Fleischer^3,4, Anthony Shock⁵, Guido Heine⁶, Capucine Daridon^1,2 and Thomas Dörner^1,2, ¹CC12, Dept. Medicine/Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, ²German Rheumatism Research Centre Berlin, Berlin, Germany, ³Charité University Medicine, Dept. Medicine/Rheumatology and Clinical Immunology/German Rheumatism Research Center (DRFZ), Berlin, Germany, ⁴Department of Medicine/Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, ⁵UCB Pharma, Slough, United Kingdom, ⁶Department of Dermatology, Venerology and Allergology, Charité University Medicine Berlin, Berlin, Germany
Background/Purpose CD22 is a negative co-receptor of the B-cell receptor (BCR) and, when targeted by epratuzumab, partially inhibits BCR signaling, for example by reducing Syk…
Abstract Number: 811 • 2014 ACR/ARHP Annual Meeting
Biologics in Takayasu Arteritis: Preliminary Data from the French Registry
Arsene Mekinian¹, Chloe Comarmond², Mathieu Resche Regon³, Tristan Mirault⁴, Jean-Emmanuel Kahn⁵, Marc Lambert⁶, Jean Sibilia⁷, Antoine Neel⁸, Miguel Hié⁹, Emmanuel Messas¹⁰, Pascal Cohen¹¹, Geraldine Muller¹², Sabine Berthier¹³, Zahir Amoura¹⁴, Isabelle Marie¹⁵, Christian Lavigne¹⁶, Marie Anne Vandenhende¹⁷, Hervé Devilliers¹⁸, Sébastien Abad¹⁹, Loic Guillevin²⁰, Mohamed Hamidou²¹, Bertrand Godeau²², Patrice Cacoub²³, Olivier Fain²⁴ and David Saadoun², ¹DHU2iB, Internal Medicine Saint Antoine Hospital, PARIS, France, ²DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ³biostatistics Saint Louis Hospital, paris, France, ⁴HEGP vascular department, paris, France, ⁵Internal Medicine, Foch Hospital, Suresnes, France, ⁶Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, ⁷Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ⁸INTERNAL MEDICINE, NANTES, France, ⁹Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ¹⁰HEGP hospital Vascular and cardiology Department, paris, France, ¹¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ¹²INTERNAL MEDICINE, DIJON, France, ¹³DIJON HOSPITAL, DIJON, France, ¹⁴Internal medicine 2, French National Reference Center for Systemic Lupus and Antiphospholipid Syndrome, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ¹⁵CHU de Rouen, Rouen, France, ¹⁶CHU d'Angers, Angers, France, ¹⁷Internal Medicine, Bordeaux, France, ¹⁸Dijon University Hospital, Department of internal medicine and systemic diseases, Dijon, France, ¹⁹Hôpital Avicenne, Bobigny, France, ²⁰Internal Medicine, Service de médecine interne, Centre de Références des Vascularites, Université Paris Descartes, APHP, Hôpital Cochin, 75005 Paris, France., Paris, France, ²¹CHU Hôtel Dieu, Nantes, Nantes, France, ²²Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Creteil, France, ²³Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, ²⁴Hôpital Saint Antoine, DHU i2B, Service de Médecine Interne, paris, France
Background/Purpose The aim of this registry is to determine: (1) the real-life use of various biological targeted treatments in Takayasu arteritis (TA) in France; (2)…
Abstract Number: 2516 • 2014 ACR/ARHP Annual Meeting
Reasons and Risk Factor for Discontinuation of Biologic Agents in Rheumatoid Arthritis Patients
Kenya Terabe¹, Toshihisa Kojima¹, Nobunori Takahashi^1,2, Koji Funahashi³, Atsushi Kaneko⁴, Yuji Hirano⁵, Yasuhide Kanayama⁶, Yuichiro Yabe⁷ and Naoki Ishiguro¹, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²65 Tsurumai-cho, Showa-ku, Nagoya University Graduate School of Medicine, Nagoya, Japan, ³Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan, ⁵Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ⁶Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, ⁷Rheumatology, JCHO Tokyo Shinjuku Medical Center, Tokyo, Japan
Background/Purpose Rheumatoid arthritis (RA) patients who failed a first biologic agent due to any reasons have the option of switching to a second one along…
Abstract Number: 1943 • 2014 ACR/ARHP Annual Meeting
In Vivo Effects of Epratuzumab, a Monoclonal Antibody Targeting Human CD22, on B Cell Function in Human CD22 Knock-in (Huki) Mice
Carolin Brandl*¹, Lamia Özgör*¹, Miriam Wöhner^1,2, Anthony Shock³ and Lars Nitschke¹, ¹Division of Genetics, University of Erlangen, Erlangen, Germany, ²Research Institute of Molecular Pathology, Vienna, Austria, ³UCB Pharma, Slough, United Kingdom
Background/Purpose Epratuzumab is a humanized monoclonal antibody that targets the B cell-specific protein CD22 currently in Phase 3 clinical trials in patients (pts) with systemic…
Abstract Number: 482 • 2014 ACR/ARHP Annual Meeting
Incidence of Opportunistic Infections in Rheumatoid Arthritis Treated with Biological Agents
Alejandro Gomez-Gomez^1,2, Zulema Rosales^1,2, Leticia Leon², Juan A Jover², Luis Rodriguez-Rodriguez² and Lydia Abasolo², ¹Rheumatology, Hospital Clinico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose With the expanding use of Biological Agents (BA), in particular TNF inhibitors, opportunistic infections (OI) are a major concern in Rheumatology. Our purposes were…
Abstract Number: 2527 • 2014 ACR/ARHP Annual Meeting
The Effect of Biological Agents on Work in Patients with Chronic Inflammatory Arthritides: A Meta-Analysis of Randomized Controlled Trials and Controlled Cohorts
Amandine Tubery¹, Cristel Castelli¹, Florence Erny¹, Françoise Barchechath-Flaisler¹, Sabrina Dadoun², Bruno Fautrel³ and Cecile Gaujoux Viala¹, ¹Nîmes University Hospital, Rheumatology Department, Nimes, France, ²Sorbonne Universités, UPMC Univ Paris 06, GRC-08, Institut Pierre Louis d’Epidémiologie et de Santé Publique, paris, France, ³Rheumatology, UPMC Paris 06 University, GRC 08, Paris France and Pitié Salpétrière Hospital Paris France, Paris, France
Background/Purpose: The addition of biological agents in treatment strategies in chronic inflammatory arthritides have improved the possibility of controlling disease activity and slowing the progression…
Abstract Number: 1942 • 2014 ACR/ARHP Annual Meeting
Regulation of the Responses of Human B Cell Subsets to Innate Immune Signals By Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22
Natalia V. Giltiay¹, Geraldine L. Shu², Anthony Shock³ and Edward A. Clark⁴, ¹Department of Immunology, Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Immunology, University of Washington, Seattle, WA, ³UCB Pharma, Slough, United Kingdom, ⁴Department of Immunology and Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose The B cell-associated receptor, CD22, functions to regulate adhesion and signaling through both the B cell receptor (BCR) and Toll-like receptors (TLRs) expressed in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].